This month's issue of the Journal features a study by McMakin et al. that examines the impact of anhedonia on the rates of recovery for adolescents with treatment-resistant depression. Based on data collected in the Treatment of Selective Serotonin Reuptake Inhibitor-Resistant Depression in Adolescents (TORDIA) study, the article establishes that anhedonia uniquely predicts a more protracted course of depression and emphasizes the importance of anhedonia for diagnosis and prognosis. Thanks to landmark studies such as the Treatment for Adolescents with Depression Study (TADS) and TORDIA, cognitive behavioral therapy and pharmacotherapy in concert are widely accepted as the evidence-based treatment of choice for depression in adolescents. However, anhedonia, a key symptom in major depression, presages a poorer outcome even in the face of well-delivered, empirically based treatments.
展开▼
